Anti-amyloid drugs (lecanemab, donanemab) and what they mean for carriers

After decades of failures, a new class of Alzheimer’s treatments, the anti-amyloid monoclonal antibodies, has reached patients. For APOE4 carriers the story cuts both ways: a real treatment option, paired with a real carrier-specific risk.

What these drugs are

Lecanemab and donanemab are antibodies that clear amyloid-beta from the brain. In large 18-month trials (CLARITY AD and TRAILBLAZER-ALZ 2), they modestly slowed the rate of cognitive decline in people with early Alzheimer’s disease. These are treatments for early, biomarker-confirmed disease. They are not a cure, and they are not preventives for people without symptoms.

The benefit, in perspective

The slowing of decline is real but modest, measured over roughly a year and a half. Whether that translates into a difference patients and families clearly notice is still debated among clinicians.

The APOE4 catch: ARIA

The most important carrier-specific issue is ARIA, short for amyloid-related imaging abnormalities, seen as brain swelling (ARIA-E) or small bleeds (ARIA-H) on MRI. ARIA is often asymptomatic but can occasionally be serious.

Here the genotype matters directly. APOE4 carriers have higher rates of ARIA, and the risk rises with each ε4 copy, so people with two copies (ε4/ε4) are at the highest risk. In the lecanemab data, symptomatic ARIA-E occurred in about 9% of ε4/ε4 homozygotes, compared with roughly 2% of heterozygotes and 1% of noncarriers. That pattern carries direct consequences:

• The FDA encourages testing your APOE genotype before treatment to inform the ARIA risk.
• Therapy requires MRI monitoring, especially in the first year.
• For some ε4/ε4 individuals the risk-benefit balance is more complicated, and it becomes an individualized conversation with a specialist.

What this means for you

• These drugs apply to early-stage disease under specialist care, not to APOE4 carriers in general.
• Genotype matters for both eligibility and safety, which reinforces the value of knowing your status with clinical guidance.
• The field is moving fast. Specifics on approvals, eligibility, and monitoring keep changing, so verify current details with a qualified clinician.

This is one of the most active areas in Alzheimer’s medicine. If it touches you or a family member, the decision belongs with a specialist who can weigh the modest benefit against the carrier-specific risks, especially for ε4/ε4.